The estimated Net Worth of Suyash Prasad is at least $3.75 million dollars as of 5 July 2022. Dr Prasad owns over 12,861 units of Taysha Gene Therapies stock worth over $1,230,966 and over the last 8 years he sold TSHA stock worth over $2,018,363. In addition, he makes $501,779 as Chief Medical Officer and Head of R&D at Taysha Gene Therapies.
Dr has made over 11 trades of the Taysha Gene Therapies stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 12,861 units of TSHA stock worth $47,586 on 5 July 2022.
The largest trade he's ever made was selling 79,000 units of Taysha Gene Therapies stock on 29 June 2021 worth over $1,787,770. On average, Dr trades about 9,905 units every 84 days since 2017. As of 5 July 2022 he still owns at least 530,589 units of Taysha Gene Therapies stock.
You can see the complete history of Dr Prasad stock trades at the bottom of the page.
Dr. Suyash Prasad FFPM, M.Sc., MBBS, M.D., M.B.B.S., F.F.P.M is the Chief Medical Officer and Head of R&D at Taysha Gene Therapies.
As the Chief Medical Officer and Head of R&D of Taysha Gene Therapies, the total compensation of Dr M at Taysha Gene Therapies is $501,779. There are 2 executives at Taysha Gene Therapies getting paid more, with Kamran Alam CPA, M.B.A. having the highest compensation of $756,381.
Dr M is 51, he's been the Chief Medical Officer and Head of R&D of Taysha Gene Therapies since . There are no older and 2 younger executives at Taysha Gene Therapies.
Suyash's mailing address filed with the SEC is C/O TAYSHA GENE THERAPIES, INC., 3000 PEGASUS PARK DRIVE, STE 1430, DALLAS, TX, 75247.
Over the last 4 years, insiders at Taysha Gene Therapies have traded over $3,159,500 worth of Taysha Gene Therapies stock and bought 21,030,825 units worth $24,949,013 . The most active insiders traders include Paul B Manning, John A Iii Stalfort et R.A. Ii Session. On average, Taysha Gene Therapies executives and independent directors trade stock every 44 days with the average trade being worth of $1,947,009. The most recent stock trade was executed by Paul B Manning on 27 June 2024, trading 1,333,333 units of TSHA stock currently worth $2,999,999.
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; and TSHA-102 for the treatment of Rett syndrome. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments; and collaboration with Yale University to advance mini-gene payloads for an AAV gene therapy for the treatment of neurodevelopmental disorders. The company was incorporated in 2019 and is based in Dallas, Texas.
Taysha Gene Therapies executives and other stock owners filed with the SEC include: